|
|
|
|
| LEADER |
03062cam a2200613 4500 |
| 001 |
PPN182434087 |
| 003 |
http://www.sudoc.fr/182434087 |
| 005 |
20240327055900.0 |
| 010 |
|
|
|a 978-1-87469-500-4
|
| 010 |
|
|
|a 1-87469-500-8
|
| 020 |
|
|
|a GB
|b 9357222
|
| 035 |
|
|
|a (OCoLC)898124372
|
| 035 |
|
|
|a ocm29358819
|
| 035 |
|
|
|a NLM9416392
|
| 035 |
|
|
|a AU@000010362868
|
| 035 |
|
|
|a DEBBGBV008551782
|
| 100 |
|
|
|a 20141215h19931993k y0spay0103 ba
|
| 101 |
0 |
|
|a eng
|2 639-2
|
| 102 |
|
|
|a GB
|
| 105 |
|
|
|a a z 001yy
|
| 106 |
|
|
|a r
|
| 181 |
|
|
|6 z01
|c txt
|2 rdacontent
|
| 181 |
|
1 |
|6 z01
|a i#
|b xxxe##
|
| 182 |
|
|
|6 z01
|c n
|2 rdamedia
|
| 182 |
|
1 |
|6 z01
|a n
|
| 183 |
|
|
|6 z01
|a nga
|2 RDAfrCarrier
|
| 200 |
0 |
|
|a Protein engineering of antibody molecules for prophylactic and therapeutic applications in man
|f edited by Mike Clark
|
| 205 |
|
|
|a 1st edition
|
| 214 |
|
0 |
|a Nottingham
|c Academic Titles
|
| 214 |
|
4 |
|d C 1993
|
| 215 |
|
|
|a 1 vol. (XI-182 p.)
|c ill., couv. ill. en coul.
|d 24 cm
|
| 320 |
|
|
|a Notes bibliogr. Index
|
| 359 |
2 |
|
|b Derivation of recombinant antibodies
|b Reshaping antibodies for therapy / E.G. Routledge, S.D. Gorman, M. Clark
|b Building an in vitro immune system: human antibodies from phage display libraries / A. Griffiths, H.R. Hoogenboom
|b Human antibodies from combinatorial libraries / D.R. Burton, C.F. Barbas III
|b Antibody effector functions
|b Effector functions of matched sels of recombinant human IgG subclass antibodies / J. Greenwood, M. Clark
|b Complement activation and Fc receptor binding by IgG / S.L. Morrison, S.M. Canfield, M. Tao
|b Molecular characterisation of IgG antibody effector sites / R. Jefferis, J. Lund
|b Chemically engineered chimeric and multi-Fab antibodies / G.T. Stevenson, M.J. Glennie, K.S. Kan
|b Therapeutic applications
|b Engineering monoclonal antibody B72.3 for cancer therapy / J.R. Adair [and others]
|b Humanised antibodies to the IL-2 receptor / C. Queen, W.P. Schneider, T.A. Waldmann
|b Clinical studies with murine and chimeric 17-1A in colorectal cancer patients / A.F. LoBuglio, M.B. Khazaeli
|
| 606 |
1 |
|
|3 PPN027880966
|a Anticorps monoclonaux
|3 PPN027323382
|x Génétique
|2 rameau
|
| 606 |
2 |
|
|3 PPN027880966
|a Anticorps monoclonaux
|3 PPN027589838
|x Thérapeutique
|2 rameau
|
| 606 |
2 |
|
|3 PPN02729014X
|a Protéines
|2 rameau
|
| 606 |
1 |
|
|3 PPN040663426
|a Anticorps monoclonaux
|3 PPN038961415
|x Génétique
|2 fmesh
|
| 606 |
2 |
|
|3 PPN040663426
|a Anticorps monoclonaux
|3 PPN038961784
|x usage thérapeutique
|2 fmesh
|
| 606 |
2 |
|
|3 PPN040802698
|a Ingénierie des protéines
|2 fmesh
|
| 610 |
0 |
|
|a Humans
|a Diseases
|a Prevention
|a Role of
|a Antibodies
|
| 676 |
|
|
|a 616.0793
|v 20
|
| 680 |
|
|
|a TP248.65.P76
|b P75 1993
|
| 686 |
|
|
|a 1993 A-910
|2 usnlm
|
| 686 |
|
|
|a QW 575
|b P967 1993
|2 usnlm
|
| 701 |
|
1 |
|3 PPN276630610
|a Clark
|b Mike
|f 1957-
|4 340
|
| 801 |
|
1 |
|a US
|b OCLC
|g AACR2
|
| 801 |
|
2 |
|a FR
|b AUROC
|g AFNOR
|
| 801 |
|
3 |
|a FR
|b Abes
|c 20240326
|g AFNOR
|
| 801 |
|
0 |
|b DNLM
|g AACR2
|
| 801 |
|
1 |
|b NLM
|g AACR2
|
| 801 |
|
2 |
|b UKM
|g AACR2
|
| 979 |
|
|
|a SAN
|
| 930 |
|
|
|5 441092101:816452210
|b 441092101
|j u
|
| 998 |
|
|
|a 214837
|
Nantilus
